CTLA4 and breast cancer: Of the six co-inhibitory ICMs, three, namely CTLA-4, PD-L1 and TIM-3, were significantly decreased (p<0.008-p<0.00001) in the group of BC patients, while BTLA, LAG-3 and TIM-3 were numerically, but not significantly decreased.